| __timestamp | Alkermes plc | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 11768000 |
| Thursday, January 1, 2015 | 4019000 | 15152000 |
| Friday, January 1, 2016 | 2301000 | 19828000 |
| Sunday, January 1, 2017 | 7232000 | 25573000 |
| Monday, January 1, 2018 | 68895000 | 23634000 |
| Tuesday, January 1, 2019 | 52816000 | 38845000 |
| Wednesday, January 1, 2020 | 1946000 | 50523000 |
| Friday, January 1, 2021 | 1020000 | 75463000 |
| Saturday, January 1, 2022 | 393842000 | 105767000 |
| Sunday, January 1, 2023 | 270806000 | 167512000 |
| Monday, January 1, 2024 | 245326000 |
Unlocking the unknown
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alkermes plc and Xenon Pharmaceuticals Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Alkermes plc's R&D expenses surged by over 3,400%, peaking in 2022 with a remarkable 394 million USD. This reflects a strategic pivot towards aggressive innovation. In contrast, Xenon Pharmaceuticals Inc. maintained a steady increase, with a notable 42% rise in 2023 compared to the previous year, reaching 168 million USD. This consistent growth underscores their commitment to sustainable innovation. The data highlights how these companies are navigating the evolving pharmaceutical landscape, with Alkermes focusing on rapid expansion and Xenon on steady growth.
Eli Lilly and Company or Alkermes plc: Who Invests More in Innovation?
Research and Development Expenses Breakdown: argenx SE vs Xenon Pharmaceuticals Inc.
Research and Development: Comparing Key Metrics for BeiGene, Ltd. and Alkermes plc
Research and Development Investment: Incyte Corporation vs Xenon Pharmaceuticals Inc.
Research and Development Investment: Summit Therapeutics Inc. vs Alkermes plc
R&D Insights: How Ascendis Pharma A/S and Xenon Pharmaceuticals Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Blueprint Medicines Corporation and Alkermes plc
Analyzing R&D Budgets: Lantheus Holdings, Inc. vs Alkermes plc
Comparing Cost of Revenue Efficiency: Alkermes plc vs Xenon Pharmaceuticals Inc.
Alkermes plc vs Supernus Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Xenon Pharmaceuticals Inc. and ImmunityBio, Inc.
Analyzing R&D Budgets: Xenon Pharmaceuticals Inc. vs Viridian Therapeutics, Inc.